Detection of immunogenic protein components in excretion/secretion products of Acanthamoeba T5 using polyclonal

Lissette Retana-Moreira1,2, Elizabeth Abrahams-Sandí1,2, Marco Ruiz-Campos1

  • 1Universidad de Costa Rica, Facultad de Microbiología, Departamento de Parasitología, San José, Costa Rica.

Abstract

Insights

Researchers developed polyclonal antibodies against Acanthamoeba proteins found in conditioned medium and extracellular vesicles. These antibodies reduced Acanthamoeba adhesion and cytopathic effects, offering potential diagnostic and therapeutic targets for infections.

Area of Science:

  • Microbiology
  • Immunology
  • Parasitology

Background:

  • Acanthamoeba is a ubiquitous protozoan parasite.
  • It causes severe infections like keratitis and granulomatous amoebic encephalitis.
  • Virulence factors in Acanthamoeba secretions are key to pathogenesis.

Purpose of the Study:

  • Identify immunogenic proteins in Acanthamoeba conditioned medium (ACM) and extracellular vesicles (EVs).
  • Utilize laboratory-produced polyclonal anti-Acanthamoeba antibodies for identification.
  • Assess the impact of these antibodies on Acanthamoeba adhesion and cytopathic effects.

Main Methods:

  • Cultured Acanthamoeba and collected excretion/secretion products (ACM, EVs).
  • Used polyclonal anti-Acanthamoeba antibodies to detect immunogenic proteins in lysates, ACM, and EVs.
  • Performed proteomic analysis to identify specific proteins.
  • Evaluated antibody effects on Acanthamoeba adhesion and cytopathic effects in vitro.

Main Results:

  • Successfully demonstrated protein recognition by anti-Acanthamoeba antibodies in all tested Acanthamoeba fractions.
  • Identified specific immunogenic protein components via proteomics.
  • Observed significant reduction in Acanthamoeba adhesion and cytopathic effects when pre-treated with antibodies.

Conclusions:

  • Developed effective polyclonal antibodies targeting pathogenic Acanthamoeba proteins.
  • These antibodies recognize virulence factors in ACM and EVs.
  • Antibodies show therapeutic potential by inhibiting Acanthamoeba adhesion and cytopathicity, aiding in the development of new diagnostic and therapeutic strategies.